Autologous Blood Clot Therapy for Wounds: Investigating the Chemotactic Effect on PBMCs and Fibroblasts in Diabetes
Summary: This in vitro study investigates the biological mechanism of topically applied autologous blood clot therapy (TABCT) for complex wounds. Researchers generated autologous clots ex vivo from 22 participants (12 controls, 10 with metabolic syndrome/type 2 diabetes – MetS/DM), cultured them for 24 hours, and analyzed the secretome for total protein, PDGF-BB, P-selectin, and CCL-5. They assessed effects on peripheral blood mononuclear cell (PBMC) chemotaxis and human dermal fibroblast migration using live-cell assays and scratch assays. MetS/DM-derived PBMCs showed heightened basal activation (increased ROS production, migration velocity, and sustained Ca²⁺ flux). Clots from MetS/DM patients released less total protein but higher P-selectin, indicating platelet hyperactivation. Despite containing measurable growth factors, the clot-derived secretome did not significantly enhance PBMC migration velocity or distance, though directionality modestly increased. Fibroblast wound closure remained limited (<30% across groups). Pretreatment with metformin, prednisone, or amoxicillin had negligible impact. The study concludes that TABCT’s clinical benefits are likely driven primarily by its fibrin scaffold properties rather than potent bioactive factor release for chemotaxis or fibroblast stimulation. Further mechanistic and translational research is needed.
Key Highlights:
- MetS/DM PBMCs exhibit heightened basal activation (↑ ROS, migration velocity, Ca²⁺ flux)
- Clot secretome shows limited enhancement of PBMC chemotaxis and fibroblast migration
- Higher P-selectin in MetS/DM clots indicates platelet hyperactivation
- Clinical benefits of TABCT likely due to fibrin scaffold, not growth factor release
- Authors: [Lead/corresponding authors not specified in abstract; full paper required for complete list]
Read full article (subscription/paywall may be required)
Keywords: autologous blood clot therapy, TABCT, diabetic wound healing, PBMC chemotaxis, fibrin scaffold